Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study

Background: Everolimus is approved for treatment of
anti-vascularendothelial growth factor (VEGF)-refractory patients
with metastaticrenal cell carcinoma (mRCC). Clinical trials rarely
mirror treatmentreality. Thus, a broader evaluation of everolimus
is valuable forroutine use. Patients and Methods: A German
multicenternon-interventional study documented mRCC patients
starting everolimusafter failure of initial VEGF-targeted therapy.
Primary endpoint waseffectiveness, defined as time to progression
(TIP) according toinvestigator assessment (time from first dose to
progression). Results:Of 382 documented patients, 196 were included
in this interim analysis.